{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-173575","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.233714+00:00","generated_at":"2026-05-17T20:38:55.845919+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Personalis Reports Q2 2025 Revenue of $17.2M, Net Loss $20.1M; Clinical Test Volume Up 59% Sequentially","bullets":["Delivered 3,478 clinical tests in Q2 2025, a 59% sequential increase over Q1 2025.","Revenue decreased 24% to $17.2M from $22.6M in Q2 2024, partly due to $5.6M decline from Natera.","Net loss was $20.1M ($0.23 per share) versus $12.8M ($0.24 per share) in Q2 2024.","Expanded Tempus AI collaboration to include colorectal cancer for exclusive commercialization.","Lowered full-year 2025 revenue guidance to $70-80M from $80-90M, citing biopharma headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-173575","json":"https://secwatch.observer/filing/0001193125-25-173575.json","markdown":"https://secwatch.observer/filing/0001193125-25-173575.md","text":"https://secwatch.observer/filing/0001193125-25-173575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525173575/0001193125-25-173575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525173575/d64395d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T20:38:55.845919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}